Aspirin (acetylsalicylic acid) lowers platelet aggregation by irreversibly blocking COX‑1, but it also removes a key prostaglandin that protects the stomach lining and helps maintain normal hemostasis.
Because of that, a number of medical conditions make the bleeding risk from aspirin higher. Below is a practical, up‑to‑date list of the main conditions that clinicians look out for when prescribing or continuing aspirin therapy.
| Category | Condition | Why it raises aspirin‑related bleeding risk |
|---|---|---|
| Gastro‑intestinal (GI) | • Peptic ulcer disease (PUD) – active or healed ulcers.
• Gastritis / H. pylori infection.
• Crohn’s disease / ulcerative colitis (especially active flare).
• GERD with erosive esophagitis.
• Previous GI bleed or bleeding tendency. | Aspirin suppresses gastric mucosal prostaglandins, making ulceration more likely and worsening existing erosions. |
| Systemic diseases that impair clotting or platelet function | • Chronic kidney disease (CKD) – especially stage 3–5.
• Hepatic impairment or cirrhosis.
• Von Willebrand disease (any type).
• Platelet function disorders (e.g., Glanzmann thrombasthenia).
• Thrombocytopenia (< 50 000 /µL, or significant drop from baseline). | CKD and liver disease cause “uremic” or “hepatic” platelet dysfunction. Von Willebrand and other platelet disorders already compromise primary hemostasis, so adding aspirin magnifies bleeding. |
| Coagulation factor deficiencies | • Hemophilia A or B (factor VIII or IX deficiency).
• Rare clotting factor deficiencies (e.g., factor XI, XIII). | Aspirin does not correct the underlying coagulation defect, and the additive platelet inhibition can tip the balance toward overt bleeding. |
| Cardiovascular/vascular conditions | • Atrial fibrillation, coronary artery disease, or post‑PCI stent placement (these are actually indications for aspirin, but they often coexist with other bleeding risk factors). | Patients on aspirin for these indications often have other comorbidities (age, CKD, GI disease) that elevate risk. |
| Hypertension | • Uncontrolled or severe hypertension (especially >180/110 mmHg). | High BP can predispose to vessel rupture, and aspirin’s antiplatelet effect can worsen it. |
| Age | • Older adults (>70 yr, especially >80 yr) | Age alone is a risk factor because of increased frailty, higher prevalence of comorbidities, and often lower platelet reserve. |
| Pregnancy & postpartum | • Pregnancy (especially 2nd/3rd trimester).
• Post‑partum hemorrhage. | Aspirin can interfere with platelet plug formation and uterine involution; it’s usually avoided except in selected cases (e.g., pre‑eclampsia prophylaxis at low dose). |
| Other chronic conditions | • Diabetes mellitus (especially with microvascular disease).
• Chronic obstructive pulmonary disease (COPD) with chronic hypoxemia (can worsen platelet dysfunction). | These conditions often coexist with other risk factors and can sensitize the vascular endothelium to bleeding. |
---
Practical Tips for Clinicians
1. Screen for GI risk – history of ulcers, dyspepsia, prior GI bleed, or concomitant NSAID/corticosteroid use.
2. Assess clotting status – check platelet count, bleeding time (if indicated), and consider a coagulation panel if liver disease or a known bleeding disorder is suspected.
3. Use gastro‑protective therapy – Proton‑pump inhibitors (PPIs) or misoprostol for high‑risk patients (e.g., age > 70 yr with history of ulcer).
4. Dose matters – 81 mg daily (“low‑dose”) has a lower GI bleed risk than 325 mg.
5. Monitor – watch for melena, hematochezia, unexplained bruising, or drops in hemoglobin.
6. Consider alternatives – if bleeding risk is too high, alternatives such as clopidogrel, ticagrelor, or non‑aspirin antiplatelets may be preferable for cardiovascular protection.
---
Bottom Line
Aspirin’s bleeding risk is amplified when a patient has:
* GI ulcer disease or active GI inflammation
* Renal or hepatic impairment
* Inherited or acquired platelet/coagulation disorders
* Severe or uncontrolled hypertension
* Advanced age
* Pregnancy (late trimester)
If any of these conditions are present, weigh the therapeutic benefit of aspirin against the heightened risk of bleeding, consider protective strategies, and adjust therapy accordingly.